Clomid Side Effects in Women: Rates, Weight Gain, Vision and OHSS

Almost every figure quoted for Clomid side effects in women traces back to one source: the adverse-reaction table in the prescribing information, built from 8,029 women treated in the trials that supported approval. It is old data, collected on the label's 50 to 100 mg five-day courses, and it remains the only large systematic count. Everything below starts from that table, then adds the warnings the label attaches to two of the effects and what the post-marketing reports and later studies add.

Below 1%, the label lists: increased appetite, constipation, rash, depression, diarrhea, dizziness, fatigue, hair loss or dry hair, increased urinary frequency, insomnia, light-headedness, nervous tension, vaginal dryness, vertigo and "weight gain/loss." Post-marketing reports add mood changes, anxiety, irritability, migraine, acne, joint and muscle pain, and raised liver enzymes, all without a frequency because they come from spontaneous reports rather than counted trials.

Most of the common effects are estrogen-withdrawal symptoms: clomiphene blocks estrogen receptors in the brain, and hot flashes, mood shifts, headaches and vaginal dryness are what a brain reading "low estrogen" produces. They start within a day or two of the first tablet and usually fade within a week of the last one, because the active isomer clears in days. The longer-lasting isomer, zuclomiphene, can be detected for more than a month, which is why some women notice effects carrying into the next cycle.

Ovarian enlargement at 13.6% is the most common entry on the table, and in most cases it means the drug did its job: a follicle, or more than one, grew. The label's management is procedural rather than alarming. A pelvic examination is required before the first and every subsequent course; if enlargement is found, the next course is held until the ovaries return to pretreatment size, and the dose or duration is reduced. Women with polycystic ovary syndrome are started on the lowest dose and shortest course because their ovaries respond more strongly.

Ovarian hyperstimulation syndrome is the severe end of that spectrum. It is uncommon with Clomid compared with injectable fertility drugs, and the label does not give a rate, but it carries its own warning because it "may progress rapidly (within 24 hours to several days) and become a serious medical disorder." The early signs the label lists are abdominal pain and distention, nausea, vomiting, diarrhea and weight gain; the severe signs are gross ovarian enlargement, fluid in the abdomen, shortness of breath and reduced urine output. The practical rule: bloating that is mild and resolves with the period is ovulation; pain with rapid weight gain, vomiting or breathlessness is a same-day call to the clinic.

The honest answer from the data is: rarely, and not much. "Weight gain/loss" sits in the label's under-1% group, not in the main table. Three things explain why many women still report it. Bloating and fluid shifts around ovulation (5.5% in the table) read as weight on a scale for a few days. Ovarian enlargement adds pelvic fullness that feels like gain. And rapid weight gain is an early warning sign of OHSS, which is the one version that should not be ignored.

There is no trial showing a sustained increase in body weight over a course of Clomid, and the drug is used for five days per cycle, which gives it little time to change body composition. A woman who gains steadily across several cycles should look at other causes, including the pregnancy she may be trying for.

Visual symptoms were reported by 1.5% of women in the trials: blurred vision, flashing lights, floaters, "waves," sensitivity to light, double vision and blind spots. The label's handling is the strictest of any side effect. Patients should be warned that these symptoms can make driving and operating machinery hazardous; any visual symptom means stopping the drug and having a prompt eye examination; and the label states that cases of prolonged visual disturbance have been reported, some beginning after the drug was stopped, and that "the visual disturbances may be irreversible, especially with increased dosage or duration of therapy."

Post-marketing reports include optic neuritis, macular edema, retinal vascular spasm, posterior vitreous detachment and "temporary or prolonged loss of vision, possibly irreversible." These are rare, but they are the reason a woman who notices any change in vision on Clomid does not finish the course first and ask later.

Hot flashes affect about one woman in ten and need no treatment beyond knowing they are coming; they cluster in the tablet days and the week after. Mood effects are harder to count: depression is in the label's under-1% list, and anxiety, irritability and mood changes appear in post-marketing reports without rates. In practice, clinicians and patients describe irritability and low mood during the course often enough that it is worth planning around, but there is no trial that measures how common it is. Women with a history of depression are not excluded from Clomid by the label; they are usually asked to report changes early.

Vaginal dryness and reduced cervical mucus are anti-estrogen effects at the cervix, listed under 1%, and they matter for a different reason: thinner mucus and a thinner uterine lining can lower the chance of conception in a cycle that otherwise worked. That is one of the mechanisms behind the gap between the roughly 80% of women who ovulate on Clomid and the roughly 30% who conceive, described in Clomid for women.

Twins are a consequence rather than a side effect, but they belong on any risk list. In the label's 2,369 documented pregnancies, 7.98% were multiple: 6.9% twins, 0.5% triplets and fewer than half a percent higher-order. A multiple pregnancy carries higher rates of prematurity and complications for mother and babies, which is why the label requires that patients be told the rate before treatment.

On birth defects, the label's position is that "available human data do not suggest an increased risk for congenital anomalies above the background population risk," and that the data show no increase in miscarriage. The long post-marketing list of fetal anomalies in the label is a list of everything ever reported, not a list of effects shown to be caused by the drug; the label itself says population studies have not supported an association.

Two label statements cover prolonged use. Patients on extended therapy may show raised serum desmosterol, a cholesterol precursor; separately, the label advises against cyclic therapy beyond about six courses. And "prolonged use of clomiphene citrate tablets USP may increase the risk of a borderline or invasive ovarian tumor," a precautionary statement; the label adds that a causal link between ovarian stimulation and ovarian cancer "has not been determined," and that infertility and never having given birth are themselves associated with ovarian cancer, which confounds the question.

Hypertriglyceridemia, in some cases with pancreatitis, appears in post-marketing reports, and the label recommends checking triglycerides in women with a personal or family history of high lipids. Liver effects are the reason liver disease is a contraindication rather than a common side effect.

Three situations do not wait for the next appointment:

Hot flashes, mild bloating, breast tenderness and a headache during the tablet days are expected and go on the list for the next visit rather than the phone. How the same drug behaves in men is a different profile, covered in Clomid side effects in men.

Clomid.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth company or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.